Arunjyoti Bio (530881)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Current Piotroski F-Score of 7/9 indicates recent financial improvement signals despite low profitability.
• Sales growth of 5.20% shows modest revenue traction.
• Reported profit growth of 105.62%, though off a tiny base, suggests momentum in earnings direction.
• Latest quarter still generated ₹6 Cr of sales, giving some operating scale to work from.

Concerns

• Price-to-book of 33.16 against book value of ₹1.96 means the market price embeds enormous expectations; no margin of safety.
• ROE of -1.90% and latest quarter net profit of ₹0 Cr show the company is not currently earning for shareholders.
• Zero dividend yield and P/E of 0.00 leave no income or earnings support for valuation.
• Promoter holding is N/A; lack of ownership disclosure is a governance red flag.

AI Analysis

Let me start with what I know. Arunjyoti Bio trades at ₹65, giving it a market cap of ₹122 crore. Yet the latest quarter shows sales of ₹6 crore and net profit of ₹0 crore. Over the full year, return on equity is -1.90% and return on capital employed is only 4.03%. So on an earnings basis, I cannot pay any amount of genuine value; the P/E is effectively zero because there is no earning power. The balance sheet is even more troubling. Book value is ₹1.96 per share, so I am being asked to pay 33 times book for a business that destroys shareholder value. This is not an investment; it is a hope. Sales growth of 5.20% is unexciting, and the reported 105.62% profit growth is off a base so low that it still produces no actual profit. There is no dividend to compensate, and promoter holding is not disclosed—a basic transparency box that should never be left blank. Ben Graham would insist on a margin of safety. Here the 52-week range of ₹5.05 to ₹65.00 tells me the market has already priced in a story, not a business. The Piotroski F-Score of 7/9 suggests some operational improvements, but a score cannot justify a 33-fold price-to-book premium when returns are negative. The industry label 'Other Financial Services' is vague; I need to know how ₹6 crore of quarterly sales becomes zero profit. If this were a durable franchise, I would see high returns on capital and pricing power. Instead I see none. I cannot value it on fundamentals, so I would not own it. The rational move is to keep my capital and wait for a price that offers a margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer